Artivion 高管在强劲的收益后抛售了股票，因为股票因成交量低而小幅下跌。 Artivion executives sold shares after strong earnings, as stock dipped slightly on low volume.

在2025年11月13日,Artivion的高管Jean Holloway和John Davis出售了股票,Holloway将自己的股份减少了3.41%和Davis减少了3.20%,两者均为每股45.86美元. On November 13, 2025, Artivion executives Jean Holloway and John Davis sold shares, with Holloway reducing her stake by 3.41% and Davis by 3.20%, both at $45.86 per share. 该公司报告说,第三季度收入强劲,16美元EPS和1.1339亿美元收入,比上一年增长18.9%。 The company reported strong third-quarter earnings, with $0.16 EPS and $113.39 million in revenue, up 18.9% year-over-year. 11月14日, Artivion 的库存以45.29美元关闭, 下跌0. 30美元, 交易量低于平均交易量。 Artivion’s stock closed at $45.29 on November 14, down $0.30, with below-average trading volume. 股票的市场上限为21.5亿美元,P/E比率为负数,协商一致的“收购”评级为49.11美元,目标为49.11美元。 The stock has a market cap of $2.15 billion, a negative P/E ratio, and a consensus “Moderate Buy” rating with a $49.11 target. 该公司开发医疗设备和植入式组织,机构持有86.37%的股份。 The company develops medical devices and implantable tissues, with 86.37% of shares held by institutions.